301281 Stock Overview
Shandong Keyuan Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and marketing of active pharmaceutical ingredients. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Shandong Keyuan Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥33.10 |
| 52 Week High | CN¥58.66 |
| 52 Week Low | CN¥18.52 |
| Beta | 0 |
| 1 Month Change | -10.66% |
| 3 Month Change | 74.76% |
| 1 Year Change | -0.03% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 19.59% |
Recent News & Updates
Shareholder Returns
| 301281 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -3.7% | -4.3% | -3.5% |
| 1Y | -0.03% | -3.4% | 10.9% |
Return vs Industry: 301281 exceeded the CN Pharmaceuticals industry which returned -3.4% over the past year.
Return vs Market: 301281 underperformed the CN Market which returned 10.9% over the past year.
Price Volatility
| 301281 volatility | |
|---|---|
| 301281 Average Weekly Movement | 15.7% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 301281's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 301281's weekly volatility has increased from 10% to 16% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 624 | Jianwei Wang | www.keyuanpharm.com |
Shandong Keyuan Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and marketing of active pharmaceutical ingredients. It offers gliclazide, for the treatment of NIDDM; metformin hydrochloride used as an adjunct to diet and exercise in adult patients with NIDDM; isosorbide mononitrate for prevention of angina pectoris and treatment of acute and chronic angina pectoris, hypertension, and myocardial infarction; isosorbide dinitrate to prevent angina pectoris due to coronary artery disease; mecobalamin for peripheral neuropathies; lansoprazole to treat acid-reflux disorders, peptic ulcer disease, h. pylori eradication, and prevention of gastrointestinal bleeds; ropivacaine hydrochloride for obstetric and regional anesthesia; isoflurane; fluoxetine hydrochloride, an anti-depression drug; clemastine fumarate, an anti-allergic agent; isoprenaline hydrochloride to treat mild or transient episodes of heart block; esmolol hydrochloride for the rapid control of ventricular rate; xanthinol nicotinate to treat of brain function barrier, cerebral embolism and cerebral thrombosis; amlexanox for treatment of aphthous ulcers; nisolsipine for hypertension; clarithromycin lactobionate; trepibutone; propafenone hydrochloride; diclofenac potassium to treat osteoarthritis and rheumatoid arthritis; chlorzoxazone for relief of discomfort associated with acute painful musculoskeletal conditions; esomeprazole sodium treats related gastric ulcer disease and zollinger-ehrlich syndrome; palonosetron hydrochloride, a chemotherapy adjuvant medication; edaravone, a cerebral protective agent; vildagliptin to treat diabetes; etamsylate, a hemostatic medication; pranoprofen that is a non-steroidal anti-inflammatory analgesic and antipyretic drugs; parecoxib sodium; and lurasidone hydrochloride, a medication for schizophrenia. The company was incorporated in 2004 and is headquartered in Jinan, China.
Shandong Keyuan Pharmaceutical Co., Ltd. Fundamentals Summary
| 301281 fundamental statistics | |
|---|---|
| Market cap | CN¥3.58b |
| Earnings (TTM) | CN¥50.17m |
| Revenue (TTM) | CN¥437.78m |
71.4x
P/E Ratio8.2x
P/S RatioIs 301281 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301281 income statement (TTM) | |
|---|---|
| Revenue | CN¥437.78m |
| Cost of Revenue | CN¥270.97m |
| Gross Profit | CN¥166.81m |
| Other Expenses | CN¥116.64m |
| Earnings | CN¥50.17m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.46 |
| Gross Margin | 38.10% |
| Net Profit Margin | 11.46% |
| Debt/Equity Ratio | 0% |
How did 301281 perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yield65%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 20:13 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shandong Keyuan Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|